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Abstract 6 
We conducted in Kenya a mixed-methods randomised controlled trial (RCT) of a 7 
nurse-led palliative care intervention integrated with anti-retroviral therapy (ART) 8 
provision for the management of HIV. Here we report qualitative findings showing 9 
increased resistance to HIV-associated stigma among trial participants. A mixed 10 
method design was chosen to enable identification of the active ingredients of the 11 
intervention and exploration of participants’ experiences of receiving the intervention. 12 
The RCT was conducted from July 2011 to November 2012 in a community hospital 13 
in the city of Mombasa, Kenya, with a sample of 120 adults with HIV on ART. Thirty 14 
participants were purposively selected to take part in a qualitative exit interview, 15 
based on study arm and mental health outcome.  16 
Inductive thematic analysis revealed increased resistance to HIV-associated stigma 17 
in both the intervention and control groups. Specifically, patients in both groups 18 
described benefit from the social support, compassionate care, and open and 19 
respectful communication they received through study participation. Participants 20 
described improved self-image, increased access to social agency, and increased 21 
resistance to HIV-associated stigma. Our findings suggest that there is potential to 22 
increase resistance to stigma through simple mechanisms of support, compassion, 23 
and improved communication in routine care. The self-reported impact of trial 24 
participation on stigma also has implications for future trials in populations in 25 
resource-constrained settings where stigma is common.  26 
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Introduction 29 
Stigma was defined by Goffman in 1963 as a mark of social disgrace, where the 30 
stigmatised are excluded from social acceptance and are socially devalued 31 
(Goffman, 1963). Although commonly understood at the individual level (Herek, 32 
Saha, & Burack, 2013a), or the macro-societal level (Parker & Aggleton, 2003), an 33 
appreciation of both acknowledges how social processes become part of a 34 
stigmatised other’s identity making resistance at an individual level very difficult 35 
(Catherine Campbell & Deacon, 2006). The persistence of HIV associated stigma, is 36 
a threat to progress in the control of HIV internationally (Stangl & Grossman, 2013), a 37 
barrier to testing (Dapaah & Senah, 2016), prevention of mother-to-child transmission 38 
(Turan & Nyblade, 2013), and, once diagnosis is confirmed, stigma remains a barrier to 39 
PLWH accessing adequate healthcare (Bogart et al., 2013; Dasgupta, Sullivan, Dasgupta, 40 
Saha, & Salazar, 2013). It is also associated with non-adherence to antiretroviral 41 
therapy (ART), increasing the risk of viral resistance (Mhode & Nyamhanga, 2016; 42 
Sweeney & Vanable, 2016).  43 
Community members often distance themselves from PLWH due to stigma (C. 44 
Campbell, Foulis, Maimane, & Sibiya, 2005; Visser & Sipsma, 2013), denying their own risk 45 
of contracting HIV, putting themselves at increased risk of transmission and delayed 46 
diagnosis (Nyblade et al., 2003). Among PLWH, the social ramifications of disclosure 47 
increase the risk of transmission through reluctance to openly take medications or 48 
negotiate condom use with a sexual partner (Mbonu, van den Borne, & De Vries, 2009; 49 
Turan & Nyblade, 2013).  50 
In addition to these public health concerns, there is evidence that people 51 
experiencing HIV-associated stigma report less healthcare utilization, and poorer 52 
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physical health (Bennett, Traub, Mace, Juarascio, & O’Hayer, 2016; Herek, Saha, & Burack, 53 
2013b). HIV-associated stigma also manifests as social isolation and rejection (C. 54 
Campbell et al., 2005; Owolabi et al., 2012), increasing depression (Palmer et al., 2011; 55 
Sumari-de Boer, Sprangers, Prins, & Nieuwkerk, 2012), anxiety (Adewuya et al., 2009) and 56 
low self-esteem (Visser & Sipsma, 2013). A recent study suggests that this relationship 57 
between HIV-associated stigma and psychological well-being may be mutually 58 
reinforcing (Miller et al., 2016).  59 
The international community struggles to identify stigma reduction interventions that 60 
are effective for HIV-related health outcomes (Stangl, Lloyd, M Brady, Holland, & 61 
Baral, 2013). Studies are often methodologically weak due to predominant use of 62 
locally-created and/or un-validated outcome measures, which inhibit interpretation 63 
and comparison across studies (Sengupta, Banks, Jonas, Miles, & Smith, 2011; 64 
Stangl et al., 2013).  65 
HIV-associated stigma also presents high costs for society (direct and indirect effects 66 
of stigma reduction have been valued at a potential $1000 per point on the Berger 67 
Stigma scale) (Brent, 2016).  68 
We conducted a randomised controlled trial (RCT) of a nurse-led palliative care 69 
intervention for PLWH established on ART in Mombasa, Kenya (Lowther et al., 2012, 70 
2014, 2015). In qualitative exit interviews, the themes of stigma, resistance to stigma, 71 
and the effects of participation in the research, emerged inductively as highly salient 72 
to participants. In this paper, we aim to describe experiences of stigma and stigma 73 
resistance among PLWH enrolled in the trial, and to draw out implications for clinical 74 
practice and research.  75 
5 
 
Materials and methods 76 
The Treatment Outcomes in Palliative Care (TOPCare) study was an RCT of a 77 
nurse-led, integrated palliative care intervention for HIV positive patients conducted 78 
in a clinic in Mombasa, Kenya. The trial had an embedded qualitative component 79 
with a sequential, explanatory design (Ivankova, Creswell, & Stick, 2006). Study 80 
methodology is reported elsewhere (Lowther et al., 2012), as are details of 81 
recruitment, follow up and missing data (Lowther et al., 2014), and results of the trial 82 
(Lowther et al., 2015). We found the intervention had significant positive effect in terms 83 
of mental health and well-being, but no effect on pain or physical outcomes (Lowther 84 
et al., 2015).  85 
The intervention consisted of 4 months of palliative care integrated into patients’ 86 
routine HIV outpatient care. It was delivered by two experienced HIV clinic nurses 87 
who received two weeks’ specialist training in palliative care from the Kenyan 88 
Hospice and Palliative Care Association and clinical support and mentoring from 89 
local hospice nurses. The training covered pain management, symptom 90 
management, nutrition, psychosocial and spiritual assessment and care, breaking 91 
bad news, ethical and legal issues, and bereavement. Participants in the intervention 92 
arm received a minimum of 7 appointments (approximately 45 minutes long) with 93 
one of the two intervention nurses. The nurse delivered person-centred care which 94 
included a holistic assessment of emotional, spiritual, social and physical well-being, 95 
patients’ understanding of HIV, and ability to maintain treatment adherence. This 96 
assessment informed care delivery, with hospice referral for complex cases of pain 97 
and symptom management. Control arm participants received standard care in the 98 
Comprehensive Care Clinic (CCC) at the study site, which consisted of monthly 99 
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appointments usually lasting 5-7 minutes. They were seen by HIV clinic nurses with 100 
similar levels of experience but without the additional training. 101 
Sampling  102 
Participants who met the inclusion criteria for the wider trial were aged ≥18, HIV 103 
positive and on ART for more than one month, and reported moderate to severe pain 104 
or symptoms lasting at least 2 weeks, as measured by the African Palliative Care 105 
Association Palliative Outcome Scale (APCA POS (Harding et al., 2010)). The sub-106 
sample recruited to the qualitative component of the study was purposively selected 107 
based on study arm allocation and individual quantitative response to participation in 108 
the trial. Participants from the intervention arm were over-sampled (10 control /20 109 
intervention) to enable in depth exploration of the active ingredients and mechanism 110 
of action of the intervention (data to be reported elsewhere). Sampling was in line 111 
with a sequential explanatory mixed methods design: we purposively selected 112 
participants to achieve a maximum variation sample based on individuals’ clinical 113 
response to the intervention. Response was measured using the Medical Outcomes 114 
Survey – HIV Mental Health Summary Score (MOS-HIV MHSS), the mental health 115 
subscale of a well-validated, disease-specific quality of life measure (Wu, 1999). A 116 
change of 10 points on the MOS-HIV MHSS is considered clinically significant (Wu, 117 
1999). Participants were categorised as “improving” if they improved by ≥10 points 118 
during the four-month study period, “static” if there was <10 points change in either 119 
direction, and “deteriorating” if they decreased by >10 points over the study period.  120 
A sample size of thirty qualitative interviews was chosen to balance opportunity for 121 
data saturation with feasibility of in-depth analysis (Sandelowski, 1995).  122 
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Data collection 123 
Data collection in both groups involved five quantitative data collection appointments 124 
at monthly intervals, with selected participants invited to take part in a qualitative 125 
interview from 1-8 months post trial exit.  126 
The same Kenyan researcher (NG) who collected the quantitative data throughout 127 
the RCT conducted the qualitative exit interviews. The researcher was skilled and 128 
experienced in qualitative research, provided with study-specific training, and 129 
bilingual in English and Swahili. The interviews lasted approximately 45 minutes, and 130 
were guided by a semi-structured topic guide developed by the study group. The 131 
topic guide included questions about participants’ physical, psychological, social and 132 
spiritual well-being before, during and after the study, in line with the holistic nature 133 
of the palliative care approach (WHO, 2013). Participants were also asked about their 134 
experiences of participating in the study, and, if allocated to the intervention arm, 135 
their perceptions of the differences between the two models of care (intervention vs 136 
standard care). 137 
The interviews were conducted in a private location at the study site in either 138 
English, Swahili or both, depending on participant preference. Participants were 139 
welcomed into the study setting, and given refreshments to demonstrate hospitality 140 
and respect. The interviews were digitally recorded, transcribed and translated into 141 
English (where needed) by an experienced translator. Translations were quality 142 
checked by the researcher against the interview recordings, and amended if 143 
inaccuracies or errors were identified. 144 
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Analysis 145 
Transcripts were analysed thematically using a combination of deductive and 146 
inductive coding (Braun & Clarke, 2006). Deductive themes were identified according 147 
to the domains of well-being integral to palliative care (physical, psychological, social 148 
and spiritual), while additional themes emerged inductively. Themes were defined as 149 
codes or collections of codes containing elements which represented a patterned 150 
response or concept (Barbour, 2013). Following Barbour, the following questions 151 
were posed to identify themes, with constant reference to the study objectives: 152 
“Which codes are repeated? How do they relate to each other? Do these codes 153 
relate as sub-themes or associates in that they occur simultaneously?” (Barbour, 154 
2013). Once identified, themes were organised hierarchically into major themes and 155 
sub-themes, according to their meaning and relationship to each other, to structure 156 
and reduce the volume of data. Major themes were those with high levels of salience 157 
and significance, in terms of understanding the therapeutic aspects of the 158 
intervention and their repetition across the dataset. Analysis was managed using 159 
NVivo 9 software. Findings are presented using anonymised illustrative quotes, 160 
annotated with the participant’s gender, age and intervention arm (Tables 2 and 3, 161 
cross-referenced in the text).  162 
Ethics 163 
Ethical approval was provided by King’s College London Research Ethics Committee 164 
(BDM/10/11-31) and the Kenyan Medical Research Institute (KEMRI/RES/7/3/1). All 165 
patients gave written informed consent (if the participant was unable to read or write, 166 
the information sheet was read aloud and a thumb print given to indicate consent). 167 
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Results 168 
Sample characteristics 169 
30 participants were interviewed; no one approached declined. Participants were 170 
similar to the wider trial sample in terms of clinical and demographic characteristics 171 
(Table 1). Mean age was 39.1, with a mean of 2.4 children and 3.2 financial 172 
dependants. Most were women (80%, n=24), and two-thirds (67.7%, n=20) 173 
completed primary school as their highest educational attainment. Interviews were 174 
conducted from one to eight months after trial exit (mean 4.2 months). The research 175 
team judged that data saturation was reached in that no new themes emerged from 176 
the analysis of later interviews.  177 
[INSERT TABLE 1 NEAR HERE] 178 
Findings 179 
Stigma arose inductively in the data as an important characteristic of participants’ 180 
experience of living with HIV, described by 25 of the 30 participants. Findings 181 
regarding stigma are presented in two themes: experience of HIV-associated stigma, 182 
and effects on HIV-associated stigma of participation in the trial. 183 
Experience of HIV-associated stigma (Table 2) 184 
When asked to describe their well-being before study participation, many participants 185 
described the experience of stigma indirectly, in terms of a fear of disclosure of their 186 
HIV diagnosis. They anticipated that this would lead to being shamed, socially 187 
isolated or discriminated against (quote 1). Participants reported hiding their status 188 
behind diagnoses which were more socially acceptable to their networks, for 189 
example saying they had tuberculosis (TB). The HIV positive diagnosis led some 190 
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participants to self-hatred and suicidal ideation. One participant described how 191 
internalised stigma, from cultural norms associating HIV with immorality, created an 192 
identity crisis (quote 2). Once they disclosed their HIV status to others, some 193 
participants reported experiencing anger and blame from their families and other 194 
community members (quote 3).  195 
Experiencing this enacted stigma or discrimination against PLWH, either directly or 196 
vicariously, discouraged participants from disclosing their status, which led to 197 
increased isolation and suffering. Social isolation was a major cause of sadness; 198 
friends from before they were diagnosed had left, increasing their sense of 199 
vulnerability and isolation (quote 4)  200 
[INSERT TABLE 2 NEAR HERE] 201 
Effects of participation in research on HIV-associated stigma (Table 3) 202 
During the counselling received in clinical appointments, intervention participants 203 
were encouraged by the study nurses to see themselves as normal, just like any 204 
other person. This was reported to improve self-esteem, self-image and acceptance, 205 
and help participants resist internalised stigma (quotes 5-7).  Some intervention arm 206 
participants described dramatic changes in their outlook, from suicidal to positive 207 
(quote 8). However, the beneficial effects of participation also extended to those 208 
PLWH in the control arm, with both groups of participants describing the therapeutic 209 
effects of their interactions with the study team (quotes 9, 10)  210 
Participants built a trusting relationship with the researcher who administered the 211 
study questionnaires, owing to the compassion they witnessed, and her non-212 
judgemental and open communication style. They described how this way they were 213 
treated, enabled them to rebuild a positive self-image (quotes 11, 12). This change in 214 
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self-regard was often described as a shift in seeing themselves as normal rather 215 
than abnormal, and worthy of respect, social interest and engagement (quotes 13, 216 
14). Participants described how, through this growth in self-esteem, they were more 217 
able to reject stigmatising messages, and became confident in disclosing their HIV 218 
positive status to their close communities (quote 15). Being treated as a normal 219 
person by a health care practitioner was in stark contrast to the advice received by 220 
one participant attending the standard clinic, who reported she was advised to 221 
‘behave normally’ when she received her diagnosis, in case people realised that she 222 
was HIV positive (quote 16).  223 
One of the most powerful aspects of participation in reducing internalised stigma was 224 
being given the space and permission to talk (quotes 17, 18). Some participants 225 
clearly attributed the effect to the process of completing the outcome measurements 226 
(quotes 19, 20). Because of participation in the study and the support they received 227 
through attending data collection appointments, some participants made concrete 228 
changes to their social situations (quote 21). Others became activists in less public 229 
ways, making themselves available to others for counselling and support, particularly 230 
those who had recently received their diagnosis. They described having the 231 
confidence and self-belief to act normally, interacting with their communities 232 
accordingly, and ignoring the stigmatising responses they had previously anticipated 233 
and feared. These newly created identities as ‘activists’ were socially acceptable and 234 
added purpose to participants’ lives participants (quotes 22, 23).  235 
[INSERT TABLE 3 NEAR HERE] 236 
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Discussion 237 
The findings of this study demonstrate the therapeutic value of a relationship 238 
characterised by compassionate care, social support, and open and non-239 
judgemental communication. While intervention group participants described benefit 240 
from their appointments with the study nurse, participants in both groups described 241 
the way that simply participating in the trial’s data collection procedures helped them 242 
to increase their resistance to the stigma associated with HIV.  243 
The researcher completed standardised patient reported outcome measures with 244 
each participant at regular intervals over a four-month time-period. She had no 245 
therapeutic remit or training, yet participants clearly described therapeutic benefit, 246 
including increasing ability to resist stigma. We can see two possible reasons for 247 
this. Firstly, the act of being asked questions about their well-being and problems 248 
may have served to acknowledge their importance. Secondly, being accepted and 249 
treated with respect may have helped patients renegotiate a positive self-identity. 250 
This second hypothesis is supported by other studies of HIV-associated stigma 251 
(Goudge, Ngoma, Manderson, & Schneider, 2009; Soskolne, 2003). In a study in South 252 
Africa, women living with HIV described how, given time, they were able to negotiate 253 
a new positive self-identity which helped them cope with anxiety and the stigma of 254 
their HIV diagnosis (Soskolne, 2003). The work of Goudge et al. (2009) describes the 255 
crucial role of social support – the very thing lacking when stigma is present and 256 
powerful - in this process (Goudge et al., 2009). They found that through social 257 
support, PLWH were able to express their emotions, make sense of their diagnosis 258 
and move towards a problem-solving approach toward managing their health, 259 
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whereas those with less support were less able to adjust and cope (Goudge et al., 260 
2009).  261 
The shift observed in our participant group can also be understood through the lens 262 
of shame and shame resistance theories. Van Vliet’s theory of shame resistance 263 
states that to improve the affected person’s self-concept individuals must undergo a 264 
process of reconstruction, rebuilding a new identity in response to a shaming 265 
experience (Van Vliet, 2008). She describes the five sub-processes this involves: 266 
connecting, refocusing, accepting, understanding and resisting (Van Vliet, 2008). 267 
These sub-processes appear to mirror our participants’ descriptions of their 268 
experience of participating in the trial. Connecting and refocusing are described 269 
when patients talk of the social support they received from the research team. 270 
Acceptance can be seen in their descriptions of learning to accommodate their HIV 271 
status, in part through the acceptance they experienced from the research team. 272 
Participants receiving the intervention described being treated as normal people, told 273 
that they were normal and advised that should treat themselves accordingly, as 274 
particularly potent aspects of the intervention. Central to acceptance was coming to 275 
understand that anyone, even morally ‘good’ people, can get HIV. The final sub-276 
process in Van Vliet’s theory is resistance. Using their reformed identity and renewed 277 
positive self-image as ‘good’ or ‘normal’ people, some participants expressed stigma 278 
resistance through becoming an activist or supporter of other PLWH. Others 279 
expressed their resistance through reaching out to rejecting family members, 280 
deciding not to be ashamed, and widely disclosing their HIV status.  281 
Our findings regarding reforming identity reflect those of Aujoulat et al.’s study 282 
(Aujoulat, Marcolongo, Bonadiman, & Deccache, 2008), in which chronically ill 283 
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patients described a process through which they managed to resolve their identities 284 
as ‘people living with a disease’, not as ‘diseased people’. Aujoulat et al. describe the 285 
processes through which individuals come to terms with a disrupted ‘well’ or ‘normal’ 286 
identity, manage the threat to their security and identity which illness represents, and 287 
face the lack of coherence or meaning which often accompanies diagnosis (Aujoulat 288 
et al., 2008). This reflects our own data and the wider HIV literature, which highlights 289 
that resistance for PLWH involves re-negotiating control over health and illness 290 
(Brinsdon, Abel, & Desrosiers, 2017; Goudge et al., 2009). 291 
Our findings suggest that healthcare systems can play a role both in perpetuating 292 
and alleviating HIV-associated stigma. Research from South Africa also describes 293 
how women attending health care settings appreciated positive interactions with 294 
staff, while negative experiences further stigmatised (Okoror, BeLue, Zungu, Adam, 295 
& Airhihenbuwa, 2014). Recent research from Bangladesh demonstrates how a 296 
sexual and reproductive health rights training package administered to health care 297 
workers can reduce the stigma experienced by their patients. This study found that 298 
indicators of HIV-associated stigma among healthcare workers were reduced, 299 
alongside an increase in patient satisfaction with services (Geibel et al., 2017). In our 300 
study, the participants witnessed a working example of supportive, stigma-free care, 301 
and help to manage stigma through the provision of space to disclose and discuss 302 
openly. 303 
An alternative explanation for the shift we observed in how participants felt could be 304 
that participants adjusted to their diagnosis over time. However, this sample of 305 
participants had been diagnosed with HIV for a median of 3.5 years (IQR 1.3-5.2) 306 
and had been on ART for a median of 2.5 years (IQR 0.8-4.2), therefore it is unlikely 307 
that this is the sole explanation. It might also be that the intervention itself, rather 308 
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than trial participation, improved stigma resistance. However, the striking similarity 309 
between the changes described by both control and intervention arm participants 310 
suggests otherwise. There was no contamination in the trial; control arm participants 311 
were seen by different clinical nurses. Additionally, the participants repeatedly 312 
referred to ‘you’ (addressing the researcher) as the one who had helped them. 313 
A limitation of the study is that the concept of stigma emerged as an inductive theme 314 
during data analysis rather than being explored explicitly in the topic guides. Data on 315 
the experience of stigma and response to stigma was therefore not collected from all 316 
participants. However, despite this, stigma was a key feature of many patients’ 317 
experiences of trial participation, described by 25 of the 30 participants. Another 318 
limitation is that, due to the inclusion criteria for the wider trial, the findings represent 319 
the experiences of PLWH who have been on ART for more than a month and are 320 
experiencing non-acute moderate to severe pain or other symptoms. However, this 321 
does not negate the importance of the experiences of this patient group. Since 322 
interviews were conducted by the same researcher who implemented the study, 323 
some social desirability bias is possible. We chose to keep the same researcher for 324 
both study components because of her experience and skill in conducting palliative 325 
care research, as we believe this skill outweighed any potential bias.  Finally, the 326 
qualitative interviews necessarily took place after the trial had finished and so could 327 
be affected by recall bias.  328 
Our findings have direct implications for clinical care and research for HIV 329 
communities, highlighting the association between psychosocial care and increased 330 
resistance to HIV-associated stigma. Failing to tackle stigma is a significant threat to 331 
infection control, access to testing, adequate treatment, and healthcare utilisation. 332 
Stakeholders at all levels of HIV care provision should consider the potential effects 333 
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of increasing levels of compassion, communication and social support in the care 334 
they provide to help PLWH resist stigma. It may be possible to integrate this 335 
approach into other, more established roles that are included in recommendations 336 
for best practice, such as treatment navigators or peer educators (Simoni, 337 
Pantalone, Plummer, & Huang, 2007; Thompson et al., 2012).  338 
Future research is needed to explore whether the hypothesised shame resistance 339 
mechanisms of connecting, refocusing, accepting, understanding and resisting do 340 
indeed contribute to stigma resistance in PLWHA. Stigma should also be measured 341 
using a standardised outcome measure such as the PLWH Stigma Index, adapted 342 
and validated in each cultural setting, to enable cross-study and cross-country 343 
comparison and service evaluation (dos Santos, Kruger, Mellors, Wolvaardt, & van der 344 
Ryst, 2014; International Planned Parenthood Federation, 2008).  345 
The findings also have implications for researchers working with socially isolated or 346 
stigmatised groups, who should consider the beneficial effects of participating in 347 
research, which may be in addition to any overt therapeutic input, in study design. 348 
This has been discussed more fully elsewhere (Lowther et al., 2016). 349 
Resistance to HIV-associated stigma is possible, and can be encouraged through 350 
compassionate communication and social support. If these findings can be replicated 351 
at a larger scale and in different contexts, this affordable and life-affirming approach 352 
could have considerable public health and clinical significance for management of 353 
the HIV pandemic. 354 
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